Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn, about a recent article by Yuxuan Wang et al, published in NEJM:
“Nice work from Bert Vogelstein’s lab published in NEJM Group
In 6 of 14 patients receiving immune checkpoint inhibitors, cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events, often before symptoms appeared.”
Title: Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events
Authors: Yuxuan Wang, Howard L. Li, Chetan Bettegowda, Kenneth W. Kinzler, Nickolas Papadopoulos, Mark Yarchoan, Bert Vogelstein
Read the Full Article on NEJM
More posts featuring Vivek Subbiah